Biblio

Export 5 results:
Author Title [ Type(Asc)] Year
Filters: Author is Ketter, Nzeera  [Clear All Filters]
Journal Article
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R., Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease., N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease., J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
S. P. Salloway, Sperling, R., Fox, N. C., Sabbagh, M. N., Honig, L. S., Porsteinsson, A. P., Rofael, H., Ketter, N., Wang, D., Liu, E., Carr, S., Black, R. S., and H Brashear, R., Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study., J Alzheimers Dis, vol. 64, no. 3, pp. 689-707, 2018.
R. H Brashear, Ketter, N., Bogert, J., Di, J., Salloway, S. P., and Sperling, R., Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies., J Alzheimers Dis, vol. 66, no. 4, pp. 1409-1424, 2018.
N. Ketter, H Brashear, R., Bogert, J., Di, J., Miaux, Y., Gass, A., Purcell, D. D., Barkhof, F., and H Arrighi, M., Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients., J Alzheimers Dis, vol. 57, no. 2, pp. 557-573, 2017.